“Very Abnormal” Trading Means There’s More Pain Ahead In The Market, According This Strategist

Here’s why the market could see greater downside than your “garden variety pullback” in the near term.

After last week’s fall, stocks have bounced back a bit this week.

After falling 2.5% last week, the S&P 500 is up 1.3% since last Friday as of Wednesday’s close. The Dow has also added 1.3%, and the Nasdaq has gained 1.8%.

But despite this week’s comeback, one expert says signs point to more pain on the horizon.

BTIG chief equity and derivatives strategist Julian Emanuel said this week there’s evidence in trading activity that indicates retail investors are still over-exposed to the market’s most expensive stocks.

“Rather than fear being priced in the options market, there’s fear of missing out,” Emanuel said. “The price of out of the money calls, as was the case throughout August, is still trading at a premium to the price of out of the monty puts. That is a very abnormal position.”

“That tells us that the public is still very committed – as are the large institutional investors,” Emanuel continued. 

Given this scenario, Emanuel says stocks are vulnerable to greater downside than your “garden variety pullback,” and we could see it before the November 3 presidential election. 

And this pullback could see the S&P 500 lose 10 – 15%, and the tech-heavy Nasdaq fall 15 – 20%.

“Markets tend to be very uncomfortable with uncertainty,” Emanuel said. “When you look at the election, it’s clear that the rhetoric is going to get nastier.”

Emanuel says, however, that the bull market is still alive. He expects the market will stabilize and investors will rotate into beaten down, economically sensitive stocks into next year.

“It really comes down to this whole idea particularly of the economy reopening,” Emanuel added. “A lot of the stocks that drove the rally in July and August are the ones that benefited from, for lack of a better word, the COVID trade.”

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More